Anakinra (Kineret®) for a hereditary autoinflammatory disease with MEFV mutation and inflammasome activation.
Latest Information Update: 08 May 2023
At a glance
- Drugs Anakinra (Primary)
- Indications Hereditary autoinflammatory diseases
- Focus Therapeutic Use
- 07 May 2023 Status changed from recruiting to completed.
- 08 Mar 2021 Results (n=3) from preliminary phase of the study published in the Rheumatology
- 21 Jul 2016 New trial record